These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 18242896)

  • 61. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size.
    Sonavane G; Tomoda K; Makino K
    Colloids Surf B Biointerfaces; 2008 Oct; 66(2):274-80. PubMed ID: 18722754
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions.
    Pu X; Sun J; Wang Y; Wang Y; Liu X; Zhang P; Tang X; Pan W; Han J; He Z
    Int J Pharm; 2009 Sep; 379(1):167-73. PubMed ID: 19505545
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability.
    Yang H; Teng F; Wang P; Tian B; Lin X; Hu X; Zhang L; Zhang K; Zhang Y; Tang X
    Int J Pharm; 2014 Dec; 477(1-2):88-95. PubMed ID: 25455766
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound.
    Sigfridsson K; Forssén S; Holländer P; Skantze U; de Verdier J
    Eur J Pharm Biopharm; 2007 Sep; 67(2):540-7. PubMed ID: 17383167
    [TBL] [Abstract][Full Text] [Related]  

  • 65. In vitro and in vivo anticancer activity of a novel puerarin nanosuspension against colon cancer, with high efficacy and low toxicity.
    Wang Y; Ma Y; Zheng Y; Song J; Yang X; Bi C; Zhang D; Zhang Q
    Int J Pharm; 2013 Jan; 441(1-2):728-35. PubMed ID: 23089583
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS).
    Friedrich I; Reichl S; Müller-Goymann CC
    Int J Pharm; 2005 Nov; 305(1-2):167-75. PubMed ID: 16242276
    [TBL] [Abstract][Full Text] [Related]  

  • 67. How do in-vitro release profiles of nanosuspensions from Alzet® pumps correspond to the in-vivo situation? A case study on radiolabeled fenofibrate.
    Hill A; Breyer S; Geissler S; Mier W; Haberkorn U; Weigandt M; Mäder K
    J Control Release; 2013 May; 168(1):77-87. PubMed ID: 23499716
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Production and characterization of Hesperetin nanosuspensions for dermal delivery.
    Mishra PR; Al Shaal L; Müller RH; Keck CM
    Int J Pharm; 2009 Apr; 371(1-2):182-9. PubMed ID: 19162147
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Alternative matrix formers for nanosuspension solidification: Dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion.
    Van Eerdenbrugh B; Froyen L; Van Humbeeck J; Martens JA; Augustijns P; Van Den Mooter G
    Eur J Pharm Sci; 2008 Nov; 35(4):344-53. PubMed ID: 18765282
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology.
    Teeranachaideekul V; Junyaprasert VB; Souto EB; Müller RH
    Int J Pharm; 2008 Apr; 354(1-2):227-34. PubMed ID: 18242898
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacokinetics and tissue distribution of liposomal etoposide in rats.
    Sistla A; Smith DJ; Kobrinsky NL; Kumar K
    Drug Deliv; 2009 Nov; 16(8):423-9. PubMed ID: 19839786
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Optimization and evaluation of Oridonin-loaded Soluplus
    Ke Z; Zhang Z; Wu H; Jia X; Wang Y
    Int J Pharm; 2017 Feb; 518(1-2):193-202. PubMed ID: 28012993
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Characterization, pharmacokinetics, tissue distribution and antitumor activity of honokiol submicron lipid emulsions in tumor-burdened mice.
    Zheng J; Tang Y; Sun M; Zhao Y; Li Q; Zhou J; Wang Y
    Pharmazie; 2013 Jan; 68(1):41-6. PubMed ID: 23444779
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Paclitaxel nanosuspensions for targeted chemotherapy - nanosuspension preparation, characterization, and use.
    Lee SE; Bairstow SF; Werling JO; Chaubal MV; Lin L; Murphy MA; DiOrio JP; Gass J; Rabinow B; Wang X; Zhang Y; Yang Z; Hoffman RM
    Pharm Dev Technol; 2014 Jun; 19(4):438-53. PubMed ID: 23617261
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice.
    Ben Zirar S; Astier A; Muchow M; Gibaud S
    Eur J Pharm Biopharm; 2008 Oct; 70(2):649-56. PubMed ID: 18582565
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Study of effect of variables on particle size of telmisartan nanosuspensions using box-Behnken design.
    Rao MR; Bajaj A
    Drug Res (Stuttg); 2014 Dec; 64(12):663-7. PubMed ID: 24549965
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.
    Karakucuk A; Celebi N; Teksin ZS
    Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetics of hydroxycamptothecin nanosuspensions in rats.
    Wang L; Hua HY; Liu WJ; Zhao YX; Zhang ZZ
    Pharmazie; 2011 Jul; 66(7):547-8. PubMed ID: 21812333
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension.
    Wang Y; Liu Z; Zhang D; Gao X; Zhang X; Duan C; Jia L; Feng F; Huang Y; Shen Y; Zhang Q
    Colloids Surf B Biointerfaces; 2011 Apr; 83(2):189-97. PubMed ID: 21176876
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions.
    Zhao YX; Hua HY; Chang M; Liu WJ; Zhao Y; Liu HM
    Int J Pharm; 2010 Jun; 392(1-2):64-71. PubMed ID: 20302926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.